These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 21484574

  • 1. Thermogenesis and related metabolic targets in anti-diabetic therapy.
    Arch JR.
    Handb Exp Pharmacol; 2011; (203):201-55. PubMed ID: 21484574
    [Abstract] [Full Text] [Related]

  • 2. Thermogenic and metabolic antiobesity drugs: rationale and opportunities.
    Clapham JC, Arch JR.
    Diabetes Obes Metab; 2007 May; 9(3):259-75. PubMed ID: 17391151
    [Abstract] [Full Text] [Related]

  • 3. A role for suppressed skeletal muscle thermogenesis in pathways from weight fluctuations to the insulin resistance syndrome.
    Dulloo AG.
    Acta Physiol Scand; 2005 Aug; 184(4):295-307. PubMed ID: 16026421
    [Abstract] [Full Text] [Related]

  • 4. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
    Weyer C, Gautier JF, Danforth E.
    Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
    [Abstract] [Full Text] [Related]

  • 5. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H, Blonde L, Rosenson R.
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [Abstract] [Full Text] [Related]

  • 6. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle.
    Corpeleijn E, Saris WH, Blaak EE.
    Obes Rev; 2009 Mar; 10(2):178-93. PubMed ID: 19207879
    [Abstract] [Full Text] [Related]

  • 7. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB, Hawley JA.
    Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
    [Abstract] [Full Text] [Related]

  • 8. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA, Montero JC, Saavedra-Gajardo I, Cerda-Flores R, Machado-Domínguez A, Comuzzie AG.
    Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
    [Abstract] [Full Text] [Related]

  • 9. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.
    Turner N, Bruce CR, Beale SM, Hoehn KL, So T, Rolph MS, Cooney GJ.
    Diabetes; 2007 Aug; 56(8):2085-92. PubMed ID: 17519422
    [Abstract] [Full Text] [Related]

  • 10. PASSCLAIM--body weight regulation, insulin sensitivity and diabetes risk.
    Riccardi G, Aggett P, Brighenti F, Delzenne N, Frayn K, Nieuwenhuizen A, Pannemans D, Theis S, Tuijtelaars S, Vessby B.
    Eur J Nutr; 2004 Jun; 43 Suppl 2():II7-II46. PubMed ID: 15221353
    [Abstract] [Full Text] [Related]

  • 11. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice.
    Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, Lee MK.
    Food Chem Toxicol; 2010 Mar; 48(3):937-43. PubMed ID: 20064576
    [Abstract] [Full Text] [Related]

  • 12. Anti-obesity effects of conjugated linoleic acid, docosahexaenoic acid, and eicosapentaenoic acid.
    Li JJ, Huang CJ, Xie D.
    Mol Nutr Food Res; 2008 Jun; 52(6):631-45. PubMed ID: 18306430
    [Abstract] [Full Text] [Related]

  • 13. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
    Laurent D, Gounarides JS, Gao J, Boettcher BR.
    Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
    [Abstract] [Full Text] [Related]

  • 14. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A, Lundsgaard C.
    Exp Clin Endocrinol Diabetes; 1998 Jun; 106 Suppl 2():29-34. PubMed ID: 9792479
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats.
    Lee HJ, Lee YH, Park SK, Kang ES, Kim HJ, Lee YC, Choi CS, Park SE, Ahn CW, Cha BS, Lee KW, Kim KS, Lim SK, Lee HC.
    Metabolism; 2009 Aug; 58(8):1170-7. PubMed ID: 19477471
    [Abstract] [Full Text] [Related]

  • 20. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
    Anandharajan R, Sayyed SG, Doshi LS, Dixit P, Chandak PG, Dixit AV, Brahma MK, Deshmukh NJ, Gupte R, Damre A, Suthar J, Padigaru M, Sharma SD, Nemmani KV.
    Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.